Stem Cell Educator therapy
Throne Biotechnologies (formerly Tianhe Stem Cell Biotechnologies)
What it is
A dialysis-like procedure that circulates a person's blood through a device where their immune cells are briefly co-cultured with cord-blood-derived stem cells, then returned — aiming to 're-educate' the immune system rather than suppress it. Small early trials reported improved C-peptide, lower HbA1c and reduced insulin dose, with minimal side effects reported in those small studies, and the proposed mechanism (immune re-balancing via cord-blood stem cells) is genuinely distinct as described. But controlled, adequately powered efficacy data are still lacking, and the registered phase 2/3 trial has been dormant on ClinicalTrials.gov for over two years with no results posted. It remains investigational.
Editorial review: .
Most recent recorded citation date: 2022-01-31. Only explicit date metadata is included; an undated citation may be newer. This does not mean every claim was reviewed on that date.
Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence
Evidence behind this assessment
Key evidence notes. Study results, product eligibility and access answer different questions.
- Who was studied?
- Study populations and analysis groups vary. Product age limits alone do not describe who was studied.
- Benefit or performance
- Beta-cell preservation: An open-label phase 1/2 study reported improved basal and stimulated C-peptide and reduced insulin dose at up to 40 weeks, including in some long-standing patients — but it was small (n=15) and lacked a blinded, randomized comparator.[1]
- Important harms and treatment burden
- Safety: In the small early studies, the procedure was reported as well tolerated with only minor venipuncture-related discomfort and no reported adverse events; as described, the stem cells stay in the device and are not infused into the patient.[1]
- Approval and country access
- Country-specific approval and access are not summarized in this record.Approval, trial recruitment, local supply and funding are separate. Check the cited label or access source.
- Follow-up and remaining uncertainty
- Durability: Authors describe lasting metabolic improvement from a single treatment, but follow-up was limited and there is no large controlled trial confirming durable beta-cell preservation.[1]
Research status alone does not establish approval, clinical benefit or local availability.
Editorial score: calculation and evidence
A weighted editorial judgment on a 0–100 scale, not a probability of success or a measured treatment effect. Higher criterion scores mean more favorable assessments.
Default calculation: 28 × 30 + 22 × 20 + 70 × 20 + 35 × 10 + 18 × 20 = 3390; divide by total weight 100. Unrounded weighted result: 33.9.
An open-label phase 1/2 study reported improved basal and stimulated C-peptide and reduced insulin dose at up to 40 weeks, including in some long-standing patients — but it was small (n=15) and lacked a blinded, randomized comparator.[1]
Authors describe lasting metabolic improvement from a single treatment, but follow-up was limited and there is no large controlled trial confirming durable beta-cell preservation.[1]
In the small early studies, the procedure was reported as well tolerated with only minor venipuncture-related discomfort and no reported adverse events; as described, the stem cells stay in the device and are not infused into the patient.[1]
Unusually broad for T1D immunotherapy — early studies treated both recent-onset and long-standing patients, including those with no residual C-peptide — but all evidence is from small single-arm cohorts.[1]
More than a decade of small international studies, but the pivotal picture has gone quiet: the registered phase 2/3 study (NCT04011020) now carries ClinicalTrials.gov's unknown-status flag — the sponsor has not verified it in over two years — its October 2024 primary completion date has passed, and no results have been posted. There is still no randomized efficacy trial and no regulatory approval.[3]
The full picture
Stem Cell Educator therapy takes an unusual angle on type 1 diabetes: instead of drugging or depleting the immune system, it tries to retrain it. In a single dialysis-like session lasting several hours, a person's blood is drawn and passed through a device where their immune cells are briefly co-cultured with multipotent stem cells derived from donated umbilical cord blood. The immune cells are then returned to the body, while the cord-blood stem cells stay behind in the device. The premise, developed by Yong Zhao and now advanced by Throne Biotechnologies, is that contact with these stem cells corrects underlying immune dysfunction — shifting cells toward regulatory, tolerance-promoting states through mechanisms the group attributes to factors such as the autoimmune regulator protein and galectin-9. Early open-label studies reported encouraging results: improved C-peptide, lower HbA1c, and reduced insulin requirements that were reported to persist for months in those small cohorts, even in some participants with long-standing disease and little residual function. The reported safety profile is a relative strength of the approach as described: the cord-blood stem cells stay in the device rather than being infused, and the small studies reported minimal side effects. The honest caveats are large, though. The supportive data come from small, mostly single-arm cohorts without the blinded, randomized, placebo-controlled design needed to prove a disease-modifying effect, and independent replication at scale is thin.
There is a newer concern too. The registered phase 2/3 trial (NCT04011020, 50 participants across two sites, sponsored by Throne Biotechnologies) has not been updated on ClinicalTrials.gov in over two years — it now carries the registry's "unknown status" flag, which means the study has passed its completion date without the sponsor verifying where it stands. Its planned primary completion date came and went in October 2024, and no results have been posted. That silence alone is not evidence that the programme has been abandoned; but for a therapy whose whole case rests on getting rigorous controlled data, that silence is itself information, and the maturity score has been marked down for it.
It is a distinctive, mechanistically interesting platform that remains firmly investigational pending rigorous controlled trials.
Coming soon
ETA · Investigational, and the public trail has gone quiet: the registered phase 2/3 study was listed as not updated in over two years with no results posted as of the last registry check. Convincing controlled efficacy data are still needed.
Sources
- [1]Reversal of type 1 diabetes via islet beta cell regeneration following immune modulation by cord blood-derived multipotent stem cells · Peer-reviewed study · 2012-01-10
- [2]Stem Cell Educator therapy in type 1 diabetes: From the bench to clinical trials · Peer-reviewed study · 2022-01-31
- [3]Clinical Application of Stem Cell Educator Therapy in Type 1 Diabetes · Trial registry — Phase 2/3, sponsor Throne Biotechnologies, target enrolment 50 across 2 sites, started September 2022. Listed as unknown status on ClinicalTrials.gov as of July 2026 — the registry's flag for a study whose sponsor has not verified it in more than two years. The primary completion date of 20 October 2024 has passed with no results posted.